SMT201700063T1 - Diagnosi di interferoni di tipo 1 - Google Patents
Diagnosi di interferoni di tipo 1Info
- Publication number
- SMT201700063T1 SMT201700063T1 SM20170063T SMT201700063T SMT201700063T1 SM T201700063 T1 SMT201700063 T1 SM T201700063T1 SM 20170063 T SM20170063 T SM 20170063T SM T201700063 T SMT201700063 T SM T201700063T SM T201700063 T1 SMT201700063 T1 SM T201700063T1
- Authority
- SM
- San Marino
- Prior art keywords
- interferon
- diagnostic
- type
- interferon diagnostic
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/249—Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39583—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials not provided for elsewhere, e.g. haptens, coenzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/136—Screening for pharmacological compounds
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
- Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Analytical Chemistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- Dermatology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Transplantation (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US23963009P | 2009-09-03 | 2009-09-03 | |
| PCT/US2010/047721 WO2011028933A1 (en) | 2009-09-03 | 2010-09-02 | Type 1 interferon diagnostic |
| EP10814513.7A EP2473636B1 (en) | 2009-09-03 | 2010-09-02 | Type 1 interferon diagnostic |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SMT201700063T1 true SMT201700063T1 (it) | 2017-03-08 |
Family
ID=43649646
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SM20170063T SMT201700063T1 (it) | 2009-09-03 | 2010-09-02 | Diagnosi di interferoni di tipo 1 |
| SM201700063T SMT201700063B (it) | 2009-09-03 | 2017-01-26 | Diagnosi di interferoni di tipo 1 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SM201700063T SMT201700063B (it) | 2009-09-03 | 2017-01-26 | Diagnosi di interferoni di tipo 1 |
Country Status (23)
| Country | Link |
|---|---|
| US (3) | US20120251546A1 (enExample) |
| EP (1) | EP2473636B1 (enExample) |
| JP (2) | JP5727484B2 (enExample) |
| KR (1) | KR20120101340A (enExample) |
| CN (1) | CN102753704A (enExample) |
| AU (1) | AU2010289383B2 (enExample) |
| BR (1) | BR112012004781A2 (enExample) |
| CA (1) | CA2772921A1 (enExample) |
| CY (1) | CY1118566T1 (enExample) |
| DK (1) | DK2473636T3 (enExample) |
| ES (1) | ES2613055T3 (enExample) |
| HR (1) | HRP20170091T1 (enExample) |
| HU (1) | HUE032917T2 (enExample) |
| LT (1) | LT2473636T (enExample) |
| ME (1) | ME02599B (enExample) |
| MX (1) | MX2012002640A (enExample) |
| PL (1) | PL2473636T3 (enExample) |
| PT (1) | PT2473636T (enExample) |
| RS (1) | RS55641B1 (enExample) |
| RU (1) | RU2012112802A (enExample) |
| SI (1) | SI2473636T1 (enExample) |
| SM (2) | SMT201700063T1 (enExample) |
| WO (1) | WO2011028933A1 (enExample) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2003237889A1 (en) * | 2002-06-11 | 2003-12-22 | Idaho Research Foundation | Type i interferon-inducible proteins to detect viral infection |
| EP2077858A4 (en) * | 2006-12-06 | 2011-07-20 | Medimmune Llc | INTERFERON ALPHA-INDUCED PHARMACODYNAMIC MARKERS |
| JP2010526107A (ja) * | 2007-05-03 | 2010-07-29 | メディミューン，エルエルシー | 自己免疫疾患の自己抗体マーカー |
| EP2701742A4 (en) * | 2011-04-26 | 2015-03-18 | Genentech Inc | COMPOSITIONS AND METHOD FOR TREATING AUTOIMMUNE DISEASES |
| WO2013101771A2 (en) * | 2011-12-30 | 2013-07-04 | Genentech, Inc. | Compositions and method for treating autoimmune diseases |
| US9493570B2 (en) * | 2012-06-13 | 2016-11-15 | Medimmune, Llc | Fixed dosage regimens for anti-type I interferon receptor (IFNAR) antibodies |
| JP6531306B2 (ja) * | 2015-02-20 | 2019-06-19 | 一三 西野 | 炎症性筋疾患鑑別マーカー及びそれを用いた炎症性筋疾患と非炎症性筋疾患の鑑別方法 |
| CN105316404B (zh) * | 2015-02-27 | 2017-02-22 | 中南大学湘雅二医院 | 系统性红斑狼疮生物标志物及其诊断试剂盒 |
| MX2018010771A (es) | 2016-03-10 | 2019-05-15 | Viela Bio Inc | Moleculas de union al transcrito 7 similar a inmunoglobulina (ilt7) y metodos de uso de las mismas. |
| CN105567861B (zh) * | 2016-03-16 | 2018-12-14 | 宫蕊 | Ifi27作为冠心病诊断标志物的用途 |
| WO2020165437A1 (en) * | 2019-02-15 | 2020-08-20 | Astrazeneca Ab | Type i interferon-mediated disorders |
| EP4058060B1 (en) | 2019-11-11 | 2025-02-19 | Astrazeneca AB | Type i interferon inhibition in systemic lupus erythematosus |
| EP4566667A3 (en) | 2020-05-29 | 2025-09-03 | AstraZeneca AB | Treatment of cardiometabolic disease with inhibitors of type i interferon signalling |
| CN116234553A (zh) * | 2020-10-02 | 2023-06-06 | 新基公司 | 治疗系统性红斑狼疮的方法和作为对疗法临床敏感性的预测指标的生物标志物的用途 |
| TW202237647A (zh) | 2020-10-08 | 2022-10-01 | 瑞典商阿斯特捷利康公司 | 狼瘡發作之治療 |
| AU2021383537A1 (en) | 2020-11-18 | 2023-06-29 | Astrazeneca Ab | Steroid sparing |
| PL4192882T3 (pl) | 2021-04-23 | 2025-04-28 | Astrazeneca Ab | Leczenie toczniowego zapalenia nerek przeciwciałem przeciwko receptorowi typu i inf anifrolumabem |
| EP4326322A1 (en) | 2021-04-23 | 2024-02-28 | Astrazeneca AB | Treatment of cutaneous lupus erythematous |
| KR20250092298A (ko) | 2021-04-23 | 2025-06-23 | 아스트라제네카 아베 | 피하 주사용 항-ifnar1 투여 요법 |
| EP4333877A1 (en) * | 2021-05-04 | 2024-03-13 | Viela Bio, Inc. | Methods of treatment of autoimmune disorders using ilt7 binding proteins |
| EP4337696A1 (en) | 2021-05-12 | 2024-03-20 | Astrazeneca AB | Inhibitor of type 1 interferon receptor steroid sparing in systemic lupus erythematosus patients |
| CA3226744A1 (en) | 2021-07-27 | 2023-02-02 | Astrazeneca Ab | Treatment of lupus |
| KR20240082399A (ko) | 2021-10-04 | 2024-06-10 | 아스트라제네카 아베 | 루푸스의 치료 |
| AU2023339761A1 (en) | 2022-09-14 | 2025-03-20 | Viatris Asia Pacific Pte. Ltd. | S1p 1 receptor modulators for use in the treatment of type 1 ifn mediated diseases |
| JP2025533978A (ja) | 2022-10-13 | 2025-10-09 | アストラゼネカ・アクチエボラーグ | ループスの治療 |
| WO2024241156A1 (en) | 2023-05-19 | 2024-11-28 | Astrazeneca Ab | Treatment of lupus |
| WO2025022280A1 (en) | 2023-07-21 | 2025-01-30 | Astrazeneca Ab | Treatment of neurodegenerative diseases |
| GB202315831D0 (en) | 2023-10-16 | 2023-11-29 | Astrazeneca Ab | Treatment of skin disease |
| GB202402824D0 (en) | 2024-02-28 | 2024-04-10 | Astrazeneca Ab | Treatment of chronic kidney disease |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS60500864A (ja) | 1983-02-04 | 1985-06-06 | ワドリ、テクナラジズ、インコーパレイティド | 近縁関係にあるが別個のタンパク質間に存在する共通決定基に対して特異的なハイブリド−マ抗体の製造および特性づけ |
| GB8303165D0 (en) | 1983-02-04 | 1983-03-09 | Secher D S | Monoclonal antibody |
| DE3306060A1 (de) | 1983-02-22 | 1984-08-23 | Boehringer Ingelheim International GmbH, 6507 Ingelheim | Neue immunglobulin-produzierende hybridzellinien, deren verwendung und verfahren zu deren herstellung |
| US4885166A (en) | 1985-06-11 | 1989-12-05 | Ciba-Geigy Corporation | Hybrid interferons |
| US7247425B2 (en) * | 1998-01-30 | 2007-07-24 | Evolutionary Genomics, Llc | Methods to identify polynucleotide and polypeptide sequences which may be associated with physiological and medical conditions |
| US7087726B2 (en) | 2001-02-22 | 2006-08-08 | Genentech, Inc. | Anti-interferon-α antibodies |
| AU2004293369A1 (en) * | 2003-03-03 | 2005-06-09 | Genentech, Inc. | Compositions and methods for the treatment of systemic lupus erythematosis |
| CA2458085A1 (en) * | 2003-03-21 | 2004-09-21 | F. Hoffmann-La Roche Ag | Transcriptional activity assay |
| CN1795010A (zh) | 2003-04-23 | 2006-06-28 | 梅达雷克斯公司 | 针对α干扰素受体－1(IFNAR－1)的人源化抗体 |
| SI2418220T1 (sl) | 2003-12-10 | 2017-10-30 | E. R. Squibb & Sons, L.L.C. | Interferon alfa protitelesa in njihova uporaba |
| EP1730308A4 (en) * | 2004-03-05 | 2008-10-08 | Rosetta Inpharmatics Llc | CLASSIFICATION OF BREAST CANCER PATIENTS USING A COMBINATION OF CLINICAL CRITERIA AND INFORMATIVE SKILLS |
| PT1781705E (pt) | 2004-06-21 | 2014-12-23 | Medarex Llc | Anticorpos contra recetor i do interferão alfa e as suas utilizações |
| PT2327792E (pt) * | 2005-08-05 | 2013-11-21 | Genentech Inc | Métodos e composições para a detecção de distúrbios autoimunes |
| US8211649B2 (en) * | 2006-03-31 | 2012-07-03 | Human Genome Sciences, Inc. | Methods of diagnosing and prognosing hodgkin's lymphoma |
| WO2008016356A2 (en) * | 2006-08-02 | 2008-02-07 | Genizon Biosciences | Genemap of the human genes associated with psoriasis |
| EP2077858A4 (en) * | 2006-12-06 | 2011-07-20 | Medimmune Llc | INTERFERON ALPHA-INDUCED PHARMACODYNAMIC MARKERS |
| JP2010526107A (ja) * | 2007-05-03 | 2010-07-29 | メディミューン，エルエルシー | 自己免疫疾患の自己抗体マーカー |
| US20100209914A1 (en) * | 2007-05-25 | 2010-08-19 | Ore Pharmaceuticals , Inc. | Methods, systems, and kits for evaluating multiple sclerosis |
| CA2714410A1 (en) * | 2008-02-08 | 2009-08-13 | Medimmune, Llc | Disease markers and uses thereof |
| WO2009130176A1 (en) * | 2008-04-21 | 2009-10-29 | Novartis Forschungsstiftung Zweigniederlassung Friedrich Miescher Institute For Biomedical Research | Antiviral Therapy |
| US20090325176A1 (en) * | 2008-06-05 | 2009-12-31 | Wyeth | Gene Expression Profiles Associated with Asthma Exacerbation Attacks |
-
2010
- 2010-09-02 HU HUE10814513A patent/HUE032917T2/hu unknown
- 2010-09-02 EP EP10814513.7A patent/EP2473636B1/en active Active
- 2010-09-02 LT LTEP10814513.7T patent/LT2473636T/lt unknown
- 2010-09-02 WO PCT/US2010/047721 patent/WO2011028933A1/en not_active Ceased
- 2010-09-02 JP JP2012528058A patent/JP5727484B2/ja not_active Expired - Fee Related
- 2010-09-02 ME MEP-2017-24A patent/ME02599B/me unknown
- 2010-09-02 BR BR112012004781A patent/BR112012004781A2/pt not_active IP Right Cessation
- 2010-09-02 ES ES10814513.7T patent/ES2613055T3/es active Active
- 2010-09-02 MX MX2012002640A patent/MX2012002640A/es not_active Application Discontinuation
- 2010-09-02 CN CN2010800447566A patent/CN102753704A/zh active Pending
- 2010-09-02 RU RU2012112802/10A patent/RU2012112802A/ru not_active Application Discontinuation
- 2010-09-02 PL PL10814513T patent/PL2473636T3/pl unknown
- 2010-09-02 SM SM20170063T patent/SMT201700063T1/it unknown
- 2010-09-02 HR HRP20170091TT patent/HRP20170091T1/hr unknown
- 2010-09-02 SI SI201031376A patent/SI2473636T1/sl unknown
- 2010-09-02 US US13/393,616 patent/US20120251546A1/en not_active Abandoned
- 2010-09-02 PT PT108145137T patent/PT2473636T/pt unknown
- 2010-09-02 CA CA2772921A patent/CA2772921A1/en not_active Abandoned
- 2010-09-02 DK DK10814513.7T patent/DK2473636T3/en active
- 2010-09-02 AU AU2010289383A patent/AU2010289383B2/en not_active Ceased
- 2010-09-02 RS RS20170089A patent/RS55641B1/sr unknown
- 2010-09-02 KR KR1020127008547A patent/KR20120101340A/ko not_active Withdrawn
-
2015
- 2015-03-18 US US14/662,134 patent/US20150191788A1/en not_active Abandoned
- 2015-04-02 JP JP2015075518A patent/JP2015147788A/ja active Pending
- 2015-10-06 US US14/876,549 patent/US20160024205A1/en not_active Abandoned
-
2017
- 2017-01-26 SM SM201700063T patent/SMT201700063B/it unknown
- 2017-01-26 CY CY20171100112T patent/CY1118566T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN102753704A (zh) | 2012-10-24 |
| CY1118566T1 (el) | 2017-07-12 |
| LT2473636T (lt) | 2017-02-10 |
| US20120251546A1 (en) | 2012-10-04 |
| BR112012004781A2 (pt) | 2017-02-14 |
| ES2613055T3 (es) | 2017-05-22 |
| PL2473636T3 (pl) | 2017-05-31 |
| EP2473636B1 (en) | 2016-10-26 |
| PT2473636T (pt) | 2017-02-06 |
| RS55641B1 (sr) | 2017-06-30 |
| RU2012112802A (ru) | 2013-10-10 |
| ME02599B (me) | 2017-06-20 |
| US20160024205A1 (en) | 2016-01-28 |
| CA2772921A1 (en) | 2011-03-10 |
| JP2013503642A (ja) | 2013-02-04 |
| DK2473636T3 (en) | 2017-02-06 |
| WO2011028933A1 (en) | 2011-03-10 |
| EP2473636A4 (en) | 2013-02-27 |
| AU2010289383B2 (en) | 2015-04-16 |
| JP5727484B2 (ja) | 2015-06-03 |
| EP2473636A1 (en) | 2012-07-11 |
| HRP20170091T1 (hr) | 2017-03-24 |
| AU2010289383A1 (en) | 2012-04-19 |
| MX2012002640A (es) | 2012-06-25 |
| HUE032917T2 (hu) | 2017-11-28 |
| JP2015147788A (ja) | 2015-08-20 |
| US20150191788A1 (en) | 2015-07-09 |
| SI2473636T1 (sl) | 2017-04-26 |
| SMT201700063B (it) | 2017-03-08 |
| KR20120101340A (ko) | 2012-09-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SMT201700063T1 (it) | Diagnosi di interferoni di tipo 1 | |
| GB0913345D0 (en) | New combination 802 | |
| EP2513131A4 (en) | NOVEL 3'-DEOXY-3'-METHYLIDENE-L-NUCLEOSIDES | |
| HK1172069A (en) | Type 1 interferon diagnostic | |
| GB0901941D0 (en) | 1007 | |
| GB0902804D0 (en) | Fusebox 2 | |
| GB0916350D0 (en) | Flexi-bend 2000 | |
| GB0921324D0 (en) | Guttergrow 2 | |
| GB0903160D0 (en) | Fusebox 4 | |
| GB0916466D0 (en) | Concept 46 | |
| GB0916473D0 (en) | Concept 52 | |
| GB0916464D0 (en) | Concept 43 | |
| GB0916463D0 (en) | Concept 40 | |
| GB0916462D0 (en) | Concept 39 | |
| GB0916461D0 (en) | Concept 38 | |
| GB0916468D0 (en) | Concept 47 | |
| GB0916460D0 (en) | Concept 37 | |
| GB0916457D0 (en) | Concept 36 | |
| GB0916469D0 (en) | Concept 48 | |
| GB0916470D0 (en) | Concept 50 | |
| GB0916456D0 (en) | Concept 35 | |
| GB0916455D0 (en) | Concept 34 | |
| GB0916471D0 (en) | Concept 51 | |
| GB0916453D0 (en) | Concept 33 | |
| GB0916465D0 (en) | Concept 44 |